Bree Foster, assistant editor at Drug Discovery News, sat down with Daniel Tillett, the CEO of Racura Oncology, to discuss G-quadruplexes, or G4 structures that are pivotal to the Australian biotech's approach to cancer.

“These G-quadruplex structures are found throughout the genome, but they’re particularly enriched in promoter regions of important genes, where they act as regulatory elements,” Tillett explained.

To read how Racura is using G4 structures in its approach to AML and lung caner, read the full article here.